Monday, March 30, 2026 – Tuesday, March 31 - An analysis of patient-reported outcomes (PROs) from the SURPASS-SWITCH trial found that adults with type 2 diabetes who switched from dulaglutide to tirzepatide not only saw stronger improvements in blood sugar and weight but also reported feeling emotionally better.
Monday, March 30, 2026 – Tuesday, March 31 - Researchers at the Institute for Bioengineering of Catalonia (IBEC) have produced a mutational map showing how mutations in amylin—a hormone that plays a key role in glucose regulation—affect its tendency to form toxic amyloid aggregates in the pancreas. This process is linked to the development of type 2 diabetes. While it was already known that certain mutations could alter this aggregation capacity, understanding of this process was fragmented and based on isolated studies. The research is published in the journal Nature Communications.
Monday, March 30, 2026 – Monday, March 30 - Accumulating scientific evidence and industry interest from Eli Lilly, Altimmune and startup Baseline Therapeutics is driving further research on the therapeutic potential of GLP-1 receptor agonists in treating substance use disorders.
Monday, March 30, 2026 – Monday, March 30 - US firm Eli Lilly, which is also pushing for end to rebate scheme, optimistic about talks with ministersBusiness live – latest updatesThe US pharmaceutical group behind the Mounjaro weight-loss drug has said it will unpause its UK investments if ministers agree to regularly increase NHS drug prices and end a rebate scheme.Patrik Jonsson, the president of Eli Lilly’s international business, said the company was in talks with UK ministers and that he was optimistic about reaching an agreement this summer for Britain to pay more for its medicines. Continue reading...
Sunday, March 29, 2026 – Sunday, March 29 - Photo Illustration by Thomas Levinson/The Daily Beast/BravoThe Real Housewives of Salt Lake City is TV’s best soap opera, week after week offering twists more shocking than secret twins and characters returning from the dead. That’s because it’s all real, happening in the most haunted suburb in the continental United States.Where else do two women connect over knowing the long-lost birth father of one’s child? Is there another city where women squabble over body positivity in a parking lot off the side of a snowy mountain? Surely, there’s no other place on Earth where Lisa Barlow could come across anywhere near a voice of reason.But that all happens here in Salt Lake City. Five episodes in, Season 5 has continued to evolve into the most captivating season in modern Real Housewives history, carried by the ever-changing bonds between our OGs and a team of wonderfully bizarre newbies.Read more at The Daily Beast.
Sunday, March 29, 2026 – Sunday, March 29 - Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that targets four gut hormones instead of the usual one to three. These next-gen tetra-functional peptides may overcome the limitations of current drugs like Ozempic and Mounjaro especially their nausea, muscle loss, and rebound weight gain.
Sunday, March 29, 2026 – Sunday, March 29 - GLP-1 drugs like Ozempic are transforming weight loss, but a new UVA study warns they're not improving a critical measure of health: cardiorespiratory fitness. While these medications help people shed fat, they also strip away vital muscle mass raising concerns about long-term heart health, physical function, and mortality. The researchers urge combining treatment with exercise, protein intake, and possibly future drugs to avoid hidden downsides of rapid weight loss.
Sunday, March 29, 2026 – Sunday, March 29 - Ozempic’s weight loss benefits might come at the cost of muscle strength, even if muscle size remains relatively stable. This raises significant concerns for older adults, who are already at risk for muscle loss and reduced mobility. Researchers stress the urgent need for human clinical trials to understand these effects fully.
Sunday, March 29, 2026 – Scientists are racing to improve weight loss treatments beyond drugs like Ozempic and Wegovy, which are effective but plagued by nausea, bone loss, and weight regain. Tufts University chemists have created a new multi-target compound that goes beyond the usual GLP-1, GIP, and glucagon approaches by adding a fourth hormone, PYY. This “quadruple-action” design aims to deliver weight loss results on par with bariatric surgery—up to 30%—without invasive procedures, and could change the future of obesity treatment.
Sunday, March 29, 2026 – GLP-1s can be a game changer, but lifestyle habits are still important.